Synbias Pharma AG
Records under this name other than the patents Synbias Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Synbias Pharma AG
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,526,290 | Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy Lapsed on the fee record Ended Jan 7, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 7, 2024 | From the USPTO record |
| US 10,294,208 | Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy Lapsed on the fee record Ended May 21, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 21, 2023 | From the USPTO record |
| US 8,846,882 | Method of producing 4-demethoxydaunorubicin Lapsed on the fee record Ended Sep 30, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 30, 2022 | From the USPTO record |
| US 8,809,549 | Esters of bendamustine and related compounds, and medical use thereof Lapsed on the fee record Ended Aug 19, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 19, 2022 | From the USPTO record |
| US 10,030,043 | Method for the synthesis of clofarabine Lapsed on the fee record Ended Jul 24, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2022 | From the USPTO record |
| US 9,765,083 | Method for the synthesis of irinotecan Lapsed on the fee record Ended Sep 19, 2021 · From the USPTO record | Lapsed on the fee record | Ended Sep 19, 2021 | From the USPTO record |